Skip to main content
OpenTrials
Completed

NCT Number: NCT01894347

Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)

Multi-Drug resistant pathogens (MDR) are reported worldwide with increasing incidence, especially in intensive care settings.

One of the drugs which are effective against MDRs, is colistin (polymyxin E). This agent has been reintroduced in response to the increase of MDR pathogens and might be used more often in the future. Data on safety regarding the most important side effects are not sufficiently available. l This study evaluates the toxicity in patients who receive aerosolized colistin.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Charité Universitätsmedizin Charité

Berlin, State of Berlin, 13353, Germany

About this study

There is growing evidence that patients in the ICU setting have a special risk profile for consecutive colonization and possible infection due to MDR pathogens.

One therapy option is the use of inhalative colistin, as this agent has been demonstrated to be effective against these pathogens. Data on pharmacodynamics or - kinetics are transferred from older studies or from other patient populations. For patients with pulmonary colonization or infection due to an MDR pathogen the systemic resorption of the drug is not known, consequently systemic side effects including kidney or neural damage are not predictable.

This study focus on patients with inhalative colistin therapy and uses therapeutic drug monitoring to determine the rate of systemic resorption of colistin. For the evaluation of neurotoxicity function of peripheral nerves (neve conduction velocity) and of the eighth cranial nerve is monitored. Nephrotoxicity is estimated by creatinine level (-clearance) and the RIFLE criteria.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • invasive ventilated patients (male and female) with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection
  • indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital

Exclusion criteria

  • Consent of the patient or of the patient´s legal representative can´t be obtained soon
  • Age < 18 years
  • Included within another, prospective clinical antibiotics-study
  • Hypersensitivity to colistin or polymyxin B
  • Patients with cystic fibrosis
  • Present letter of attorney or patient´s provision, which precludes a priori the participation in studies
  • Missing consent for storage of pseudonymised data in context of the study
  • The patient is in an institution due to a court injunction or administrative order

Treatment and study plan

TDM, Monitoring of Neuro-and Nephropathology

Other

Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology

Primary outcomes

  1. Number and frequency of adverse events (nephro- or neurotoxicity after aerosolised colistin therapy)

    Time frame: 28 days

    Adverse events are measured based on validated criteria:

    • creatinine-clearance and RIFLE-criteria
    • Neuromonitoring (nerve conduction velocity, EEG)

Secondary outcomes

  1. Serum concentration of colistin and β-Lactam antibiotics

    Time frame: 3 days

    Colistin-concentration in serum following inhalative therapy (in mg/L) 2 hours and 8 hours of application and in steady state on day 3 of therapy

  2. Serum levels of colistin and β-Lactam antibiotics (e.g. Meropenem)in mg/L

    Time frame: 3 days

    Serum drug levels in mg/L 2hours, 8 hours and 3 days (steady state) after therapy induction

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Registry information

Acronym: LOKALE

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jul 10, 2013
Registry last updated
Aug 3, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.